



PRESS RELEASE

For Immediate Release

Corgenix Medical Expands Distribution of AspirinWorks® Test

DENVER, Colo. — January 25, 2008 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that the number of laboratories offering its AspirinWorks® test is continuing to expand. The product is now available to physicians and laboratories across the United States, Europe, South America, Mexico, Israel and Japan.

“A significant number of labs, including some of the largest providers of diagnostic testing, are now routinely running this important test, which determines if aspirin is eliciting an effect,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “In the quarter ended December 31, 2007, we continued to add important new customers in the U.S. and internationally, and we expect this degree of growth to continue into 2008. This is great news for the increasing number of physicians wanting access to the AspirinWorks test.”

About AspirinWorks®

The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B₂ (11dhTxB₂) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The product received clearance in May 2007 by the U.S. Food and Drug Administration for *in vitro* diagnostic use in the United States. Unlike other tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test requires a urine sample that can easily be obtained in any doctor’s office.

The AspirinWorks test measures the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin’s target). The stickier the blood platelets, the less impact the aspirin is having.

The AspirinWorks product will be featured at several upcoming scientific meetings, including the American College of Family Physicians in March and the American College of Cardiology in March.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.

William Critchfield, Senior VP and CFO

Phone: 303-453-8903

Email: writchfield@corgenix.com

Media Contact:

Dan Snyders

Vice President, Public Relations Supervisor

Armada Medical Marketing

Phone: 303-623-1190 x 230

Fax: 303-623-1191

dan@armadamedical.com